Positive Surgical Margins Linked to Worse RCC Recurrence, Survival Rates
Findings may inform treatment decisions after nephrectomy with positive surgical margins.
Findings may inform treatment decisions after nephrectomy with positive surgical margins.
Change in subcutaneous fat after initiation of immune checkpoint inhibitors may distinguish which patients will and will not respond to therapy.
Partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
Lenvatinib plus pembrolizumab improved outcomes vs sunitinib in patients with advanced renal cell carcinoma.
Investigators concluded that pN1 RCC could be stratified into pN1 and pN2, with pN2 conferring a poor prognosis comparable to that of non-metastatic stage IV pN0 disease.
A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.
Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma.
A novel imaging technique, 89Zr-DFO-girentuximab PET/CT, can accurately and noninvasively identify clear cell renal cell carcinoma, a study suggests.
Cabozantinib can produce responses in patients with advanced clear cell RCC whose disease progressed on first-line checkpoint inhibitor-based therapy, a phase 2 study suggests.
A higher starting dose of lenvatinib is associated with better health-related quality of life in patients with renal cell carcinoma.